Background: Recently, epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI) has been developed in a hardly imaging speed and became one of the main ways of clinical treatment for non-small cell lung cancer. We had synthesized a novel EGFR TKI HYGF as a targeted agent for the molecular imaging of tumors that drug sensitivity for EGFR TKI. In this study ,the novel radiopharmaceutical, 99Tcm-hydrazido(HYNIC)-HYGF, was synthesized and evaluated for its labeling rate, purity,stability. Methods: HYGF was labeled with 99Tcm using HYNIC as bifunctional chelator, EDDA and Tricine as coligands under the different conditions. Monolayer chromatography for quality control had been used for testing the labeling rate and ten section method had been taken to calculate the radioactive distribution. Results: The best conditions for labeling was EDDA 10mg, Tricine 20mg, HYNIC-HYGF 30ug, SiCl2 20mg, addition nitrogen and heating wit 100℃ in ten minutes. The agents was clarify, colorless and transparent liquid in the end of experiments. Conclusion: The agents, labeling rate was over 95%, can be directly used for SPECT imaging to screen the advantage patients in clinical and detect the treatment effects of EGFR TKI.
目的:评估Deep 球囊扩张膝关节以下动脉及支架置入治疗糖尿病足的临床疗效及其安全性。方法:选择 2007 年 8 月~2011年 8 月我院收治的96 例糖尿病足患者并将其随机分成A、 B 两组, A 组(74 例)使用deep 球囊扩张膝关节以下细小动脉甚至足背动脉, 合并股动脉狭窄者植入支架; B 组(22 例)单纯给以抗凝、 扩血管、 溶栓及相关治疗。 分别观察记录和比较治疗前、 后及术后1 周、 1、 3、 6、 10 个月患者下肢及足部皮肤颜色、 温度、静息痛、 足背动脉搏动、 间歇性跛行、 溃疡愈合情况。结果: (1)糖尿病足的血管病变多为膝关节下的动脉, 包括胫前、 胫后、 腓动脉以及以下分支, 常累及双侧数支动脉, 呈阶段性分布; (2)A、 B 组的有效率分别为 88.32%和 48.63%, A 组显著高于 B 组(P<0.05); (3)溃疡愈合情况: 0-2 期 A 组: 100%愈合, B 组 83.72%; 3-4 期 A 组 56.25%愈合, B 组18.46%, 对于溃疡治疗的有效率 A 组显著高于 B 组(P<0.05)。结论: Deep 球囊扩张糖尿病足膝关节以下动脉联合动脉支架术治疗糖尿病足与保守治疗相比, 效果明显,可恢复下肢动脉血供, 明显消除和缓解静息痛、 间歇性跛行,促进溃疡的愈合。 降低截肢的几率。改善生活质量。